Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tyra Biosciences, Inc. Director's Dealing 2021

Sep 15, 2021

32575_dirs_2021-09-14_f01b2fec-50be-44f2-9f43-306734f170c5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-09-14

Reporting Person: Alta Partners NextGen Fund II Management, LLC (10% Owner)
Reporting Person: Alta Partners NextGen Fund II, L.P. (10% Owner)
Reporting Person: Hudson Peter A (10% Owner)
Reporting Person: JANNEY DANIEL (10% Owner)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 112929 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Preferred Stock $0.00 Common Stock (3148365) Indirect
Series B Preferred Stock $0.00 Common Stock (662752) Indirect

Footnotes

F1: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports.

F2: The shares of Series A Preferred Stock and Series B Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1-for-2.5974. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1-for-2.5974. The Series A Preferred Stock and Series B Preferred Stock has no expiration date.